The Danish Innovation Fund has granted Oncoral Pharma ApS 497.310 DKK as an Innobooster grant to support an open label phase I study to show that their proprietary oral irinotecan tablet product can be taken together with oral capecitabine tablet as a new, safe and effective tablet based treatment to be taken at home.